A Phase 3 interventional study of 1PC002 and Lipitor in Hypercholesterolemia, sponsored by Orient Pharma Co., Ltd.. Completed at 8 sites in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-17.
Sponsored by Orient Pharma Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 9th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 3, and was the 17th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2011.
This study's enrollment of 202 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 200 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
Orient Pharma Co., Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Orient Pharma Co., Ltd. has 2 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
1PC002 is a newly developed synthetic and highly potent HMG-CoA reductase inhibitor. Its active compound, pitavastatin has recently been approved by US FDA for indications of primary hypercholesterolemia and combined dyslipidaemia. It exhibits unique pharmacokinetic properties. Unlike atorvastatin which is metabolized by CYP3A4, metabolism of 1PC002 does not depend on CYP3A4. This multi-center study is conducted to confirm the efficacy and safety of 1PC002 administered for 12 weeks is non-inferior to atorvastatin.
This is a prospective, active-controlled, double-blind, randomized, parallel, and multi-center study. To target 150 evaluable subjects, approximately 200 Taiwanese patients with primary hypercholesterolemia or combined dyslipidemia will be enrolled in this study.
After providing the written inform consent, patients will undergo a complete physical examination, vital sign (brachial BP / HR), medical history, and lab assessment, including fasting serum LDL-C, TC, HDL-C, TG, and non-HDL. They should not take any hypolipidemic drugs for at least 4 weeks prior to initiation of study treatment. All eligible subjects will be randomized into 2 groups in a 1:1 ratio to receive either 2 mg 1PC002 or 10 mg atorvastatin once daily for 12 weeks.
After entering the baseline visit, lipid profiles (including fasting serum LDL-C, TC, HDL-C, TG, non-HDL, Apo A1, Apo B and Apo B / Apo A1 ratio), hs-CRP, eGFR, spot urinary albumin / creatinine ratio (ACR) and central BP values will be obtained at baseline, Week 4 and Week 12 for evaluating the effectiveness of study drugs and for any possible changes in laboratory data. Non-HDL value will be calculated by subtracting HDL-C from TC. Moreover, serum Cystatin C, another biomarker of renal function, will also be assessed at baseline and Week 12.
For monitoring the safety, biochemical and hematological assessment will be performed at baseline, Week 4 and 12. Additional liver function and CK test will be conducted at Week 8. The occurring AE(s) and SAE will be followed until resolution or the event is considered stable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who meet All of the following diagnosis at screening visit:
Exclusion Criteria:
Subjects with the following lab data at screening visit:
Subject with the following past histories:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 mg 1PC002 once daily for 12 weeks.
Drug: 1PC002
10 mg atorvastatin once daily for 12 weeks.
Drug: Lipitor
Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
Also known as: Pitavastatin
Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
Also known as: Atorvastatin
The Percentage Change From Baseline in LDL-C Level at Week 12.
The study aimed to test that the efficacy of 1PC002 group was non-inferior to Atorvastatin group in percent change from baseline of LDL-C level at Week 12.
Time frame: 12 weeks
LDL-C
Percent change from baseline in LDL-C level at Week 4
Time frame: week 4
HDL-C
Percent change from baseline in HDL-C level at Week 4
Time frame: week 4
Triglyceride
Percent change from baseline in TG level at Week 4
Time frame: week 4
| Milestone | 1PC002 | Lipitor |
|---|---|---|
| Started | 103 | 99 |
| Completed | 87 | 81 |
| Not completed | 16 | 18 |
The study aimed to test that the efficacy of 1PC002 group was non-inferior to Atorvastatin group in percent change from baseline of LDL-C level at Week 12.
| Percent change from baseline | Lipitor | 1PC002 |
|---|---|---|
| The Percentage Change From Baseline in LDL-C Level at Week 12. | -42.89 ± 12.80 | -37.43 ± 17.97 |
Percent change from baseline in LDL-C level at Week 4
| Percent change from baseline | 1PC002 | Lipitor |
|---|---|---|
| LDL-C | -39.01 ± 13.04 | -40.07 ± 12.18 |
Percent change from baseline in HDL-C level at Week 4
| Percent change from baseline | 1PC002 | Lipitor |
|---|---|---|
| HDL-C | 0.06 ± 10.49 | -1.64 ± 11.01 |
Percent change from baseline in TG level at Week 4
| Percent change from baseline | 1PC002 | Lipitor |
|---|---|---|
| Triglyceride | -18.75 ± 26.9 | -19.5 ± 25.5 |
Collected over 12-16 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1PC002 | — | 3/103 (2.9%) | 58/103 (56.3%) |
| Lipitor | — | 1/99 (1%) | 55/99 (55.6%) |
| Event | 1PC002 | Lipitor |
|---|---|---|
| Congestive heart failureCardiac disorders | 0/103 | 1/99 |
| Cellulitis,right handInfections and infestations | 1/103 | 0/99 |
| Rheumatic heart disease with Moderate Calcified Mitral stenosisCardiac disorders | 1/103 | 0/99 |
| Urinary tract infectionsInfections and infestations | 1/103 | 0/99 |
| Event | 1PC002 | Lipitor |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 11/103 | 9/99 |
| Blood creatine phosphokinaseInvestigations | 9/103 | 6/99 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/103 | 6/99 |
| InsomniaPsychiatric disorders | 1/103 | 4/99 |
| Back painMusculoskeletal and connective tissue disorders | 4/103 | 1/99 |
| DizzinessNervous system disorders | 4/103 | 1/99 |
| MicroalbuminuriaRenal and urinary disorders | 1/103 | 3/99 |
| PruritusSkin and subcutaneous tissue disorders | 2/103 | 3/99 |
| Oedema peripheralGeneral disorders | 3/103 | 1/99 |
| Hepatic enzyme increasedInvestigations | 3/103 | 0/99 |
| Age, Categorical(Participants) | 1PC002 | Lipitor | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 87 | 93 | 180 |
| >=65 years | 16 | 6 | 22 |
| Age, Continuous(years) | 1PC002 | Lipitor | Total |
|---|---|---|---|
| Mean | 55.36 ± 10.50 | 57.90 ± 8.80 | 56.60 ± 9.76 |
| Sex: Female, Male(Participants) | 1PC002 | Lipitor | Total |
|---|---|---|---|
| Female | 60 | 57 | 117 |
| Male | 43 | 42 | 85 |
| Ethnicity (NIH/OMB)(Participants) | 1PC002 | Lipitor | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 103 | 99 | 202 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | 1PC002 | Lipitor | Total |
|---|---|---|---|
| Taiwan | 103. | 99 | 202 |
The record gives a start of Nov 2011, a primary completion of Sep 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2023, 10 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin
Orient Pharma Co., Ltd.